Ruotong Yang
Ruotong Yang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Hongbo Chen
Department of Epidemiology and Biostatistics, School of Public Health Peking University Health Science Center Beijing China
5 shared publicationsHuan Yu
Department of Epidemiology and Biostatistics, School of Public Health Peking University Health Science Center Beijing China
5 shared publicationsJunhui Wu
Department of Epidemiology and Biostatistics, School of Public Health Peking University Health Science Center Beijing China
5 shared publicationsMengying Wang
Department of Epidemiology and Biostatistics, School of Public Health Peking University Health Science Center Beijing China
5 shared publicationsSiyue Wang
Department of Epidemiology and Biostatistics, School of Public Health Peking University Health Science Center Beijing China
5 shared publicationsTao Wu
Department of Epidemiology and Biostatistics, School of Public Health Peking University Health Science Center Beijing China
5 shared publications
Latest Publications
Impact of comprehensive tobacco control policies on stroke and acute myocardial infarction among patients with hypertension and type 2 diabetes in Beijing, China: An interrupted time‐series analysis
Background and aims: Tobacco control policies enhance cardiovascular health at the population level, but their effects on high‐risk individuals, such as those with type 2 diabetes mellitus (T2DM) or hypertension, remain unclear. This study evaluated the association between a tobacco control policy and hospital admissions for stroke and acute myocardial infarction (AMI) in hypertensive and T2DM individuals. Design: Interrupted time series study. Setting: Beijing, China. Participants: 2 144 133 hypertensive and 1 446 750 T2DM patients residing in Beijing from January 2013 to June 2017. Intervention: A comprehensive tobacco control policy package, incorporating all MPOWER components, was implemented in June 2015. Measurements: Changes in admission rates and admissions for stroke and AMI. Findings: Patients with T2DM showed immediate decreases in stroke [−9.4% (95% confidence interval = −13.3% to −5.3%)] and AMI [−24.3% (−31.2% to −16.7%)] admission rates after the policy. Similarly, the immediate post‐policy change in stroke and AMI admission rates for hypertensive patients was −7.5% (−10.9% to −3.9%) and −23.0% (−29.2% to −16.3%), respectively. However, these reductions did not differ from those without either condition ( P ‐interaction >0.05). For long‐term trends, significant decreases were only seen for stroke [T2DM: −32.9% (−39.9% to −25.1%); hypertension: −33.3% (−39.3% to −26.7%)], but not AMI admissions, and again did not differ from those without either disease ( P ‐interaction >0.05). Compared with healthy controls without T2DM or hypertension, patients with both conditions showed greater long‐term reductions in stroke admission rates [−29.2% (−37.0% to −20.5%) vs. −14.4% (−26.3% to −0.5%), P ‐interaction = 0.05), whereas the opposite trend was observed for AMI admissions [7.9% (−15.9% to 38.4%) vs. −29.9% (−46.9% to −7.3%), P ‐interaction = 0.02]. Conclusions: Beijing's 2015 comprehensive tobacco control policy appears to be associated with reduced acute myocardial infarction and stroke admissions among high‐risk groups (individuals with type 2 diabetes mellitus and hypertension), although admission rates showed no statistically significant difference between high‐risk and non‐high‐risk populations.
Impact of comprehensive tobacco control policies on stroke and acute myocardial infarction among patients with hypertension and type 2 diabetes in Beijing, China: An interrupted time‐series analysis
Background and aims: Tobacco control policies enhance cardiovascular health at the population level, but their effects on high‐risk individuals, such as those with type 2 diabetes mellitus (T2DM) or hypertension, remain unclear. This study evaluated the association between a tobacco control policy and hospital admissions for stroke and acute myocardial infarction (AMI) in hypertensive and T2DM individuals. Design: Interrupted time series study. Setting: Beijing, China. Participants: 2 144 133 hypertensive and 1 446 750 T2DM patients residing in Beijing from January 2013 to June 2017. Intervention: A comprehensive tobacco control policy package, incorporating all MPOWER components, was implemented in June 2015. Measurements: Changes in admission rates and admissions for stroke and AMI. Findings: Patients with T2DM showed immediate decreases in stroke [−9.4% (95% confidence interval = −13.3% to −5.3%)] and AMI [−24.3% (−31.2% to −16.7%)] admission rates after the policy. Similarly, the immediate post‐policy change in stroke and AMI admission rates for hypertensive patients was −7.5% (−10.9% to −3.9%) and −23.0% (−29.2% to −16.3%), respectively. However, these reductions did not differ from those without either condition ( P ‐interaction >0.05). For long‐term trends, significant decreases were only seen for stroke [T2DM: −32.9% (−39.9% to −25.1%); hypertension: −33.3% (−39.3% to −26.7%)], but not AMI admissions, and again did not differ from those without either disease ( P ‐interaction >0.05). Compared with healthy controls without T2DM or hypertension, patients with both conditions showed greater long‐term reductions in stroke admission rates [−29.2% (−37.0% to −20.5%) vs. −14.4% (−26.3% to −0.5%), P ‐interaction = 0.05), whereas the opposite trend was observed for AMI admissions [7.9% (−15.9% to 38.4%) vs. −29.9% (−46.9% to −7.3%), P ‐interaction = 0.02]. Conclusions: Beijing's 2015 comprehensive tobacco control policy appears to be associated with reduced acute myocardial infarction and stroke admissions among high‐risk groups (individuals with type 2 diabetes mellitus and hypertension), although admission rates showed no statistically significant difference between high‐risk and non‐high‐risk populations.
- 18 September 2024
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 78 (12) , 776-782
Association of benzodiazepine and Z‐hypnotic use with cardiovascular disease risk: insights from a prospective study of 10 million people in China
Aim: To assess the association between Benzodiazepines (BZDs) or Z‐hypnotic use and cardiovascular diseases (CVD) incidence in residents in Beijing, China.Methods: We included 2,415,573 individuals with a prescription record for BZDs or Z‐hypnotics in the Beijing Medical Claim Data for Employees database during 2010–2017, and 8,794,356 non‐users with other prescriptions for the same period. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using Cox proportional risk models for 712,850 exposed and 712,850 unexposed participants who were matched 1:1 by propensity score.Results: BZDs or Z‐hypnotics users had a higher risk of CVD than non‐users, with an HR of 1.11 (95% CI: 1.10, 1.13). Compared with non‐users, those who used them for less than 3 months had the lowest risk of CVD, and those for more than 5 years had the highest risk, with HRs of 0.50 (0.48, 0.51) and 1.78 (1.72, 1.83), respectively. The risk of CVD was relatively low in those who used only one of the long‐acting BZDs, short‐acting BZDs, or Z‐hypnotics compared to unexposed individuals. Individuals exposed to all three types of drugs had the highest risk, 2.33 (2.22, 2.44) times that of non‐users. Users below the median dose had a lower risk of CVD compared to non‐users, whereas users exceeding the median dose had an increased risk.Conclusion: BZD or Z‐hypnotic use in general was nominally associated with an elevated risk of CVD. However, for short‐term, single‐type, and low‐to‐moderate‐dose users, not only did this elevated risk disappear, but drug use also demonstrated a protective effect.
- 18 September 2024
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 78 (12) , 776-782
Association of benzodiazepine and Z‐hypnotic use with cardiovascular disease risk: insights from a prospective study of 10 million people in China
Aim: To assess the association between Benzodiazepines (BZDs) or Z‐hypnotic use and cardiovascular diseases (CVD) incidence in residents in Beijing, China.Methods: We included 2,415,573 individuals with a prescription record for BZDs or Z‐hypnotics in the Beijing Medical Claim Data for Employees database during 2010–2017, and 8,794,356 non‐users with other prescriptions for the same period. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using Cox proportional risk models for 712,850 exposed and 712,850 unexposed participants who were matched 1:1 by propensity score.Results: BZDs or Z‐hypnotics users had a higher risk of CVD than non‐users, with an HR of 1.11 (95% CI: 1.10, 1.13). Compared with non‐users, those who used them for less than 3 months had the lowest risk of CVD, and those for more than 5 years had the highest risk, with HRs of 0.50 (0.48, 0.51) and 1.78 (1.72, 1.83), respectively. The risk of CVD was relatively low in those who used only one of the long‐acting BZDs, short‐acting BZDs, or Z‐hypnotics compared to unexposed individuals. Individuals exposed to all three types of drugs had the highest risk, 2.33 (2.22, 2.44) times that of non‐users. Users below the median dose had a lower risk of CVD compared to non‐users, whereas users exceeding the median dose had an increased risk.Conclusion: BZD or Z‐hypnotic use in general was nominally associated with an elevated risk of CVD. However, for short‐term, single‐type, and low‐to‐moderate‐dose users, not only did this elevated risk disappear, but drug use also demonstrated a protective effect.
- 18 September 2023
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 57 (1) , 132-142
Effect of statin therapy patterns on readmission and mortality in patients with intracerebral hemorrhage
There is limited and inconsistent evidence for the association of statin therapy and statin treatment patterns with the risk of recurrent intracerebral hemorrhage (ICH) in patients with prior ICH. To assess the association of statin therapy and its intensity, type, initiation time, and discontinuation with the risk of recurrent ICH and mortality in Chinese patients with ICH. Patients with newly diagnosed ICH in the Beijing Employee Medical Claims Data database from 2010 to 2017 were included. Post-ICH statin users (post-diagnosis only) and nonusers (never), statin discontinuers (pre-diagnosis only) and continuers (pre- and post-diagnosis) were matched on a 1:1 propensity score, respectively. Adjusted Cox proportional risk models were used to estimate the risk ratios for ICH readmission and mortality under various statin patterns. A total of 2668 post-ICH statin users and 2668 nonusers without a history of statin use were enrolled. Post-ICH statin users had a lower risk of ICH readmission (HR, 0.57; 95% CI 0.48, 0.69) and all-cause death (0.56: 0.49, 0.63) than nonusers. Low/moderate-intensity treatment was associated with a 63% lower risk of recurrent ICH compared with nonusers (0.37: 0.29, 0.46), whereas high-intensity treatment did not reduce the risk (0.93: 0.74, 1.16). Both low/moderate-intensity (0.42: 0.36, 0.48) and high-intensity statins (0.57: 0.48, 0.69) were associated with a lower risk of all-cause mortality. The risk of ICH readmission was 53% (0.47: 0.30, 0.74) lower with adherence to rosuvastatin than with atorvastatin. Only starting medication within 30 days of the first diagnosis of ICH reduced the risk of ICH readmission (0.49: 0.40, 0.60). Among patients with a history of statin use, 1807 discontinuing and 1,807 continuing users of statins were included. The risk of ICH readmission (4.00: 3.32, 4.80) and the risk of all-cause death (4.01: 3.57, 4.50) were substantially increased in statin discontinuation compared with continued statin use. Statin therapy after ICH was associated with lower risks for ICH readmission and all-cause mortality compared with non-statin therapy, especially at low/moderate intensity and early initiation of statins after ICH. Adherence to rosuvastatin was associated with a lower risk of recurrence of ICH than atorvastatin. Among patients with a statin history prior to ICH, discontinuation of statins after ICH was associated with increased risk of ICH recurrence and death.
- 18 September 2023
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 57 (1) , 132-142
Effect of statin therapy patterns on readmission and mortality in patients with intracerebral hemorrhage
There is limited and inconsistent evidence for the association of statin therapy and statin treatment patterns with the risk of recurrent intracerebral hemorrhage (ICH) in patients with prior ICH. To assess the association of statin therapy and its intensity, type, initiation time, and discontinuation with the risk of recurrent ICH and mortality in Chinese patients with ICH. Patients with newly diagnosed ICH in the Beijing Employee Medical Claims Data database from 2010 to 2017 were included. Post-ICH statin users (post-diagnosis only) and nonusers (never), statin discontinuers (pre-diagnosis only) and continuers (pre- and post-diagnosis) were matched on a 1:1 propensity score, respectively. Adjusted Cox proportional risk models were used to estimate the risk ratios for ICH readmission and mortality under various statin patterns. A total of 2668 post-ICH statin users and 2668 nonusers without a history of statin use were enrolled. Post-ICH statin users had a lower risk of ICH readmission (HR, 0.57; 95% CI 0.48, 0.69) and all-cause death (0.56: 0.49, 0.63) than nonusers. Low/moderate-intensity treatment was associated with a 63% lower risk of recurrent ICH compared with nonusers (0.37: 0.29, 0.46), whereas high-intensity treatment did not reduce the risk (0.93: 0.74, 1.16). Both low/moderate-intensity (0.42: 0.36, 0.48) and high-intensity statins (0.57: 0.48, 0.69) were associated with a lower risk of all-cause mortality. The risk of ICH readmission was 53% (0.47: 0.30, 0.74) lower with adherence to rosuvastatin than with atorvastatin. Only starting medication within 30 days of the first diagnosis of ICH reduced the risk of ICH readmission (0.49: 0.40, 0.60). Among patients with a history of statin use, 1807 discontinuing and 1,807 continuing users of statins were included. The risk of ICH readmission (4.00: 3.32, 4.80) and the risk of all-cause death (4.01: 3.57, 4.50) were substantially increased in statin discontinuation compared with continued statin use. Statin therapy after ICH was associated with lower risks for ICH readmission and all-cause mortality compared with non-statin therapy, especially at low/moderate intensity and early initiation of statins after ICH. Adherence to rosuvastatin was associated with a lower risk of recurrence of ICH than atorvastatin. Among patients with a statin history prior to ICH, discontinuation of statins after ICH was associated with increased risk of ICH recurrence and death.
- 11 May 2023
- Published by SAGE Publications in International Journal of Stroke
- Vol. 18 (8) , 948-956
Is statin therapy after ischaemic stroke associated with increased intracerebral hemorrhage? The association may be dependent on intensity of statin therapy
Background: There has been concern that statin therapy may be associated with an increased risk of intracerebral hemorrhage (ICH). We investigated whether the intensity and type of statin therapy instituted after ischemic stroke (IS) were associated with risk of future ICH in a region of northern China with a high incidence of stroke. Methods: Newly diagnosed IS patients who were not treated with lipid-lowering drugs in the Beijing Employee Medical Claims Data database from 2010 to 2017 were included. The primary exposure variable was any statin prescription within 1 month of the first documented stroke diagnosis. High-intensity statin therapy was defined as atorvastatin ⩾ 80 mg, simvastatin ⩾ 80 mg, pravastatin ⩾ 40 mg, and rosuvastatin ⩾ 20 mg per day or equivalent combination. An adjusted Cox proportional hazards model was used to estimate the hazard ratio (HR) for ICH during follow-up in groups exposed and not exposed to statins. Results: Of 62,252 participants with IS and 628 ICH readmissions were recorded during a median follow-up of 3.17 years. The risk of ICH among statin users (N = 43,434) was similar to that among nonusers (N = 18,818) with an adjusted HR and 95% confidence interval (CI) of 0.86 (0.73, 1.02). Compared with non-statin therapy, patients with low/moderate-intensity therapy had a lower risk of ICH (0.62: 0.52, 0.75), while patients with high-intensity therapy had a substantially higher risk (2.12: 1.72, 2.62). For patients with different types of statin therapy, adherence to rosuvastatin had the lowest risk of ICH compared to adherence to atorvastatin (0.46: 0.34, 0.63), followed by simvastatin (0.60: 0.45, 0.81). Conclusion: In patients with IS, any statin therapy was not associated with an increased risk of ICH. However there appeared to be differential risk according to the dose of statin with high-intensity statin therapy being associated with an increased risk of ICH, while low/moderate-intensity therapy was associated with a lower risk.
- 11 May 2023
- Published by SAGE Publications in International Journal of Stroke
- Vol. 18 (8) , 948-956
Is statin therapy after ischaemic stroke associated with increased intracerebral hemorrhage? The association may be dependent on intensity of statin therapy
Background: There has been concern that statin therapy may be associated with an increased risk of intracerebral hemorrhage (ICH). We investigated whether the intensity and type of statin therapy instituted after ischemic stroke (IS) were associated with risk of future ICH in a region of northern China with a high incidence of stroke. Methods: Newly diagnosed IS patients who were not treated with lipid-lowering drugs in the Beijing Employee Medical Claims Data database from 2010 to 2017 were included. The primary exposure variable was any statin prescription within 1 month of the first documented stroke diagnosis. High-intensity statin therapy was defined as atorvastatin ⩾ 80 mg, simvastatin ⩾ 80 mg, pravastatin ⩾ 40 mg, and rosuvastatin ⩾ 20 mg per day or equivalent combination. An adjusted Cox proportional hazards model was used to estimate the hazard ratio (HR) for ICH during follow-up in groups exposed and not exposed to statins. Results: Of 62,252 participants with IS and 628 ICH readmissions were recorded during a median follow-up of 3.17 years. The risk of ICH among statin users (N = 43,434) was similar to that among nonusers (N = 18,818) with an adjusted HR and 95% confidence interval (CI) of 0.86 (0.73, 1.02). Compared with non-statin therapy, patients with low/moderate-intensity therapy had a lower risk of ICH (0.62: 0.52, 0.75), while patients with high-intensity therapy had a substantially higher risk (2.12: 1.72, 2.62). For patients with different types of statin therapy, adherence to rosuvastatin had the lowest risk of ICH compared to adherence to atorvastatin (0.46: 0.34, 0.63), followed by simvastatin (0.60: 0.45, 0.81). Conclusion: In patients with IS, any statin therapy was not associated with an increased risk of ICH. However there appeared to be differential risk according to the dose of statin with high-intensity statin therapy being associated with an increased risk of ICH, while low/moderate-intensity therapy was associated with a lower risk.